Pulmonx CORP Form 4 insider transactions

Pulmonx Corporation Director, Georgia Melenikiotou, was granted 37,153 Restricted Stock Units (RSUs) on June 2, 2025, increasing her beneficial ownership to 99,714 shares.

Pulmonx Corporation's Chief Commercial Officer, Geoffrey Beran Rose, reported the sale of 6,947 shares of common stock on June 2, 2025, to satisfy tax withholding requirements related to the vesting of Restricted Stock Units.

Pulmonx Corporation's General Counsel, David Aaron Lehman, sold 10,457 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Pulmonx Corp. Director Daniel P. Florin was granted 37,153 Restricted Stock Units (RSUs) as part of his compensation, aligning his interests with shareholders.

Pulmonx Corporation Director Dana G. Mead Jr. reported the acquisition of 37,153 shares through a Restricted Stock Unit grant and an additional 4,076 shares via a trust liquidation distribution.

Director Glendon E. French III of Pulmonx Corp sold 20,000 shares of common stock at an average price of $7.85, executed under a pre-arranged 10b5-1 trading plan.

Mehul Joshi, CFO of Pulmonx Corp, reports the sale of shares to cover tax obligations and the acquisition of shares through a stock purchase plan and RSU grant.

Pulmonx CEO Steven S. Williamson reports the sale of shares to cover tax obligations, acquisition of shares through the employee stock purchase plan, grant of restricted stock units, and grant of employee stock options.

David Aaron Lehman, General Counsel of Pulmonx Corp, sold shares to cover tax obligations related to vesting Restricted Stock Units and received a grant of additional RSUs.

Chief Commercial Officer Geoffrey Beran Rose sold shares of Pulmonx Corp to cover tax obligations related to vesting Restricted Stock Units (RSUs) and received a grant of additional RSUs.

Director Glendon E. French III of Pulmonx Corp sold a portion of his holdings in common stock on February 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

A Pulmonx Corp director, Glendon E. French III, sold a total of 4,547 shares of common stock over two days under a pre-arranged 10b5-1 trading plan.

A Pulmonx Corp executive, Geoffrey Beran Rose, sold a total of 4,378 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Pulmonx Corp's General Counsel, David Aaron Lehman, sold a total of 5,497 shares of common stock to cover tax obligations related to vesting of restricted stock units.

A Pulmonx Corp director, Glendon E. French III, sold 20,000 shares of common stock at an average price of $6.63, as part of a pre-arranged 10b5-1 trading plan.

Director Glendon E. French III of Pulmonx Corp sold 20,000 shares of common stock on October 17, 2024, at a weighted average price of $6.52.

Director Glendon E. French III of Pulmonx Corp sold 20,000 shares of common stock on September 12, 2024, at a weighted average price of $8.09.

Chief Commercial Officer of Pulmonx Corp, Rose Geoffrey Beran, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

David Aaron Lehman, General Counsel of Pulmonx Corp, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units (RSUs).

Pulmonx Corporation's CEO, Steven S. Williamson, purchased 14,245 shares of common stock at an average price of $6.84 on August 20, 2024.

Chief Commercial Officer of Pulmonx Corp, Rose Geoffrey Beran, sold 1,184 shares of common stock on June 24, 2024, at a price of $6.16 per share.

Director Thomas William Burns reports acquisition and disposal of Pulmonx Corp common stock on June 3, 2024, according to a Form 4 filing.

Director Richard Ferrari reports acquisition of common stock and grant of restricted stock units in Pulmonx Corp.

Director Daniel P. Florin of Pulmonx Corp reports acquiring 15,216 shares of common stock through a grant of Restricted Stock Units.

Director Tiffany Sullivan reports acquisition and disposal of Pulmonx Corp common stock on June 3, 2024, according to a Form 4 filing.

David Aaron Lehman, General Counsel of Pulmonx Corp, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Geoffrey Beran Rose, Chief Commercial Officer of Pulmonx Corp, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Director Glendon E. French III of Pulmonx Corp acquired 15,216 shares of common stock through a grant of Restricted Stock Units.

Director Mead Dana G Jr. reports acquiring 15,216 shares of Pulmonx Corp through a restricted stock unit grant and disposing of 4,076 shares via a liquidation distribution.

Director Georgia Melenikiotou of Pulmonx Corp [LUNG] received a grant of 15,216 common stock shares on June 3, 2024.